Worldwide, approximately 50 million people live with epilepsy, a quarter of which are treated with antiepileptic drugs (AEDs). Therapeutic drug monitoring (TDM) of AEDs is often necessary to assess therapeutic compliance, potential drug-drug interactions, and pharmacokinetic inter-and intravariability secondary to significant differences in excretion and metabolism. TDM is necessary to minimize the destructive toxicities of AEDs including hematopoietic dysfunction, pruritus, rash, Steven-Johnson syndrome, anxiety, agitation, suicidal ideation, liver failure, gastrointestinal issues, and neurologic dysfunction. Tandem mass spectrometry with stable isotope internal standards is the gold standard for the measurement of AEDs. Here, we present a rapid ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the simultaneous measurement of gabapentin, lamotrigine, levetiracetam, monohydroxy derivative (MHD) of oxcarbazepine (the main, active oxcarbazepine metabolite, also known as licarbazepine), and zonisamide in serum. Methods: For analysis, 20 µL serum samples were added to acetonitrile in the presence of deuterated internal standards for protein precipitation. After centrifugation, 10 µL of supernatant was added to 90 µL of water. Ten µL of this solution was injected into a C18 column for reversed phase UPLC chromatographic separation. Quantification of analytes was accomplished using positive-mode electrospray ionization and collision-induced dissociation MS. Total run time was 3 minutes. Assay parameters were evaluated according to Food and Drug Administration (FDA) bioanalytical guidelines. Results: To guide our assay development, we evaluated the range of AED levels for our patient population from lab results assayed at a reference laboratory. Over the course of one year, 1,825 total samples were assayed. One levetiracetam drug level was greater than 100 ug/mL, and the lower limit of quantification (LLOQ) for all drugs analyzed ranged between 2 ug/mL and 0.2 ug/mL. Therefore, an assay range of 0.1 ug/mL to 100 ig/mL was chosen for all analytes and was linear (r2 > .999) from 0.1 ug/mL to 100 ug/mL. This assay demonstrated acceptable accuracy and precision (%DEV <20% and %CV <20% for the LLOQ, %DEV <15% and %CV <15% at all other levels tested), linearity across the reportable range (r2 > .999, slopes ranging 0.968-1.062), carryover, stability under relevant storage conditions, matrix effects, recovery, and extraction and processing efficiency in accordance with FDA guidelines. Additionally, a cross-comparison with a reference laboratory using a similar methodology was performed.
Conclusions: A rapid, high-throughput, and robust UPLC-MS/MS method for monitoring multiple antiepileptics was developed and validated to address the clinical needs of our patient population. 
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UHRF2 Is Expressed in Human Diffuse
University of Minnesota Medical School, Minneapolis
Objective: Diffuse large B cell lymphoma (DLBCL) is a neoplasm of large B lymphocytes with a diffuse growth pattern. Though morphologically homogeneous, there is heterogeneity in DLBCL biology. The World Health Organization (WHO) has divided DLBCL into different prognostic categories based on morphology, genetics, immunophenotype, and clinical presentation. Ubiquitinlike with PHD and ring finger domains 2 (UHRF2) protein is involved in cell-cycle regulation and is an important transcriptional co-activator of E2F1-induced cell death genes. Prior studies have suggested that UHRF2 may interact with p53. In previous studies, we demonstrated that UHRF2 varies in expression and localization in diverse human cancers, including one case of non-Hodgkin lymphoma. In the current study, our major objectives were to characterize the expression of UHRF2 in human DLBCL and correlate its expression patterns with pathologic and clinical features; the long-term outcome is to understand whether UHRF2 is an important regulator of DLBCL biology. Methods: After receiving an internal review board waiver, we performed a natural language search of the pathology database to identify nodal, primarily de novo, adult human DLBCL cases diagnosed at the University of Minnesota between 2003 and 2016. Hematoxylin and eosin (H&E) slides were reviewed by two authors (MF and ML) to verify the diagnosis and evaluate for specimen adequacy. After excluding needle core biopsies, 37 samples (36 patients) were included to construct a DLBCL tissue microarray (TMA). Clinical data were collected through electronic medical record searches. Control tissues from spleen, thymus, bowel, tonsil, and appendix, as well as the 37 samples were spotted randomly in triplicate to construct a 128-spot TMA. TMA slices were stained with H&E and CD3, Ki67, PAX-5, p53, and UHRF2 immunostains. All samples were evaluated by light microscopy and scored by two authors (MF and ML). Results: Cases represented 18 men and 18 women, with a mean age at diagnosis of 64 (range 21-84). All cases of DLBCL expressed UHRF2; however, there was variability in UHRF2 expression. We categorized cases into © American Society for Clinical Pathology AJCP / Meeting AbstrActs "high" and "low" UHRF2 expressing groups. Cases among the "high" group were more likely to be associated with a greater proportion of nuclei that overexpressed the p53 gene product (Fisher exact test, P < .05). However, UHRF2 expression did not correlate with a high Ki67 defined proliferative index, high percent tumor infiltrating T cells, nuclear PAX-5 expression, germinal center subtype, or overall survival. Conclusions: We conclude that UHRF2 is universally expressed in all DLBCL cases in our study, and there is an association between high expression of UHRF2 and overexpression of the p53 protein. This association may implicate a role of UHRF2 in lymphomagenesis and/or tumor maintenance in the subset of DLBCL cases that express high levels of p53.
Inaccurate Hemoglobin S+C Estimates Prior to Emergent Red Blood Cell Exchange Procedures Lead to Overtransfusion
Jeffrey Papiernik, Ronald Jackups;Washington University, St Louis, MO Background: As a therapeutic treatment for sickle cell disease, red blood cell (RBC) exchange rapidly removes unwanted hemoglobin (Hgb) S and C and replaces it with donated RBC units containing mainly Hgb A. Determining how much blood to deliver to reach the targeted goal, however, requires laboratory testing for the current measure of abnormal hemoglobin. If results are unknown prior to the start of the procedure, especially in emergent situations, the level must be estimated. We investigated to what degree these estimates led to inappropriate overtransfusion or undertransfusion in our patient population. Methods: This was a retrospective, observational study from 2011 to 2016 of patients who had completed one or more RBC exchange procedures in the inpatient setting at a large academic medical center. The following information was obtained: history of disease, number of procedures received, emergent status of procedures, number of RBC units per procedure, goal Hgb S+C percentage, goal fraction of cells remaining (FCR), and Hgb S+C percentages measured pre-and postprocedure. Procedures that lacked any of the latter three pieces of information were not included in the analysis. Estimated preprocedural Hgb S+C percentage was calculated by dividing the Hgb S+C goal by the FCR. Overtransfusion and undertransfusion were determined by comparing the original FCR to an FCR calculated using the actual preprocedural and goal Hgb S+C percentages. Results: During the study period, 378 RBC exchange procedures were assessed. Three primary groups of procedures were evaluated: emergent procedures with unknown preprocedural Hgb S+C percentage (E-U), nonemergent procedures with unknown preprocedural Hgb S+C percentage (NE-U), and procedures with known preprocedural Hgb S+C percentage (Kn). The percent difference between the estimated and actual preprocedural Hgb S+C levels was calculated for each procedure. The median difference (and range) for the E-U, NE-U, and Kn groups was 26.6% (-9.8%-270.4%), 1.6% (-33.5%-311.0%), and 1.3% (-19.5%-118.0%), respectively. The E-U group was significantly different from the other two groups (P < .0001), but the NE-U group was not different from the Kn group (P = .16). Undertransfusion occurred in 14% of procedures by a total of 38 RBC units, and overtransfusion in 39% of procedures by a total of 167 RBC units. Approximately 1/2 of the excess 167 units came from emergent procedures, despite comprising less than 20% of the total procedures. Conclusions: More than half of RBC exchange procedures (53%) resulted in the patient receiving an incorrect number of RBC units, mostly overtransfusion attributable to emergent procedures in which the lab results were still pending by the time the procedures began. These results suggest that a rapid turnaround time method should be available to measure abnormal hemoglobin levels prior to the start of RBC exchange. 
